Condition: Recurrent Endometrial Cancer · Sponsor: University of Miami
The purpose of this study is to determine the efficacy and safety of Pembrolizumab in combination with Lenvatinib in recurrent, mismatch repair-proficient endometrial cancer after failure of first-line therapy with a platinum-based doublet chemotherapy and immunotherapy.
This description comes directly from the study's public registry record.
Navya Nair, MD, MPH · 305-243-2233 · navya.nair@miami.edu
Abdulrahman Sinno, MD · 305-243-2233 · axs3193@miami.edu
Always discuss trial participation with your own doctor first.
| University of Miami | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07594015